Literature DB >> 20161373

Endosomal Toll-like receptors in autoimmunity: mechanisms for clinical diversity.

Sapna Trivedi1, Eric L Greidinger.   

Abstract

The endosomal Toll-like receptors (TLR3, TLR7 and TLR9) have been implicated in the pathogenesis of autoimmune diseases. Their signaling pathways show remarkable similarities and yet the outcomes following activation of each of these TLRs lead to clinically distinct autoimmune disease phenotypes. This review discusses how differences may arise at a molecular and cellular level to account for this diversity of responses. Understanding the roles of individual TLR pathways and the relationships between them and non-TLR innate immune pathways in the pathogenesis of diseases such as systemic lupus erythematosis highlights potential treatment targets for this spectrum of autoimmune diseases.

Entities:  

Year:  2009        PMID: 20161373      PMCID: PMC2779546          DOI: 10.2217/thy.09.2

Source DB:  PubMed          Journal:  Therapy        ISSN: 1475-0708


  75 in total

Review 1.  TLR signaling.

Authors:  Taro Kawai; Shizuo Akira
Journal:  Semin Immunol       Date:  2007-02-01       Impact factor: 11.130

Review 2.  Gene expression profiling in human autoimmunity.

Authors:  Emily C Baechler; Franak M Batliwalla; Ann M Reed; Erik J Peterson; Patrick M Gaffney; Kathy L Moser; Peter K Gregersen; Timothy W Behrens
Journal:  Immunol Rev       Date:  2006-04       Impact factor: 12.988

3.  NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses.

Authors:  Konstantin D Taganov; Mark P Boldin; Kuang-Jung Chang; David Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-02       Impact factor: 11.205

4.  Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies.

Authors:  A A Bengtsson; G Sturfelt; L Truedsson; J Blomberg; G Alm; H Vallin; L Rönnblom
Journal:  Lupus       Date:  2000       Impact factor: 2.911

5.  Deletion of TLR3 alters the pulmonary immune environment and mucus production during respiratory syncytial virus infection.

Authors:  Brian D Rudd; Jetse J Smit; Richard A Flavell; Lena Alexopoulou; Matthew A Schaller; Achim Gruber; Aaron A Berlin; Nicholas W Lukacs
Journal:  J Immunol       Date:  2006-02-01       Impact factor: 5.422

6.  The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes.

Authors:  M A Tomai; L M Imbertson; T L Stanczak; L T Tygrett; T J Waldschmidt
Journal:  Cell Immunol       Date:  2000-07-10       Impact factor: 4.868

7.  Tissue targeting of anti-RNP autoimmunity: effects of T cells and myeloid dendritic cells in a murine model.

Authors:  Eric L Greidinger; Yunjuan Zang; Irina Fernandez; Mariana Berho; Mehdi Nassiri; Laisel Martinez; Robert W Hoffman
Journal:  Arthritis Rheum       Date:  2009-02

8.  Glucocorticoids inhibit IRF3 phosphorylation in response to Toll-like receptor-3 and -4 by targeting TBK1 activation.

Authors:  Claire E McCoy; Susan Carpenter; Eva M Pålsson-McDermott; Linden J Gearing; Luke A J O'Neill
Journal:  J Biol Chem       Date:  2008-03-20       Impact factor: 5.157

9.  Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner.

Authors:  Mark Rutz; Jochen Metzger; Tanja Gellert; Peter Luppa; Grayson B Lipford; Hermann Wagner; Stefan Bauer
Journal:  Eur J Immunol       Date:  2004-09       Impact factor: 5.532

10.  High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus.

Authors:  T B Niewold; J Hua; T J A Lehman; J B Harley; M K Crow
Journal:  Genes Immun       Date:  2007-06-21       Impact factor: 2.676

View more
  8 in total

1.  The Activation of Human Dermal Microvascular Cells by Poly(I:C), Lipopolysaccharide, Imiquimod, and ODN2395 Is Mediated by the Fli1/FOXO3A Pathway.

Authors:  Lukasz Stawski; Grace Marden; Maria Trojanowska
Journal:  J Immunol       Date:  2017-11-15       Impact factor: 5.422

2.  Cytokines regulate cysteine cathepsins during TLR responses.

Authors:  Blaine M Creasy; Kathleen L McCoy
Journal:  Cell Immunol       Date:  2010-11-19       Impact factor: 4.868

3.  Semaphorin 3A is a marker for disease activity and a potential immunoregulator in systemic lupus erythematosus.

Authors:  Zahava Vadasz; Tharwat Haj; Katalin Halasz; Itzhak Rosner; Gleb Slobodin; Dina Attias; Aharon Kessel; Ofra Kessler; Gera Neufeld; Elias Toubi
Journal:  Arthritis Res Ther       Date:  2012-06-14       Impact factor: 5.156

4.  Toll-like receptor 3 in liver diseases.

Authors:  Shi Yin; Bin Gao
Journal:  Gastroenterol Res Pract       Date:  2010-09-23       Impact factor: 2.260

5.  The biological significance of evolution in autoimmune phenomena.

Authors:  Carlos A Cañas; Felipe Cañas
Journal:  Autoimmune Dis       Date:  2012-03-14

6.  Variety of endosomal TLRs and Interferons (IFN-α, IFN-β, IFN-γ) expression profiles in patients with SLE, SSc and MCTD.

Authors:  A Paradowska-Gorycka; A Wajda; B Stypinska; E Walczuk; E Rzeszotarska; M Walczyk; E Haladyj; K Romanowska-Prochnicka; A Felis-Giemza; A Lewandowska; M Olesińska
Journal:  Clin Exp Immunol       Date:  2021-01-17       Impact factor: 5.732

Review 7.  U1-RNP and Toll-like receptors in the pathogenesis of mixed connective tissue diseasePart II. Endosomal TLRs and their biological significance in the pathogenesis of mixed connective tissue disease.

Authors:  Agnieszka Paradowska-Gorycka
Journal:  Reumatologia       Date:  2015-08-07

Review 8.  Adjuvant Effect of Toll-Like Receptor 9 Activation on Cancer Immunotherapy Using Checkpoint Blockade.

Authors:  Yu-Chen Chuang; Jen-Chih Tseng; Li-Rung Huang; Chun-Ming Huang; Chi-Ying F Huang; Tsung-Hsien Chuang
Journal:  Front Immunol       Date:  2020-05-29       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.